二甲双胍给药对肾癌患者癌症特异性生存、总生存、无进展生存和疾病进展的影响系统回顾和荟萃分析

IF 0.2 Q4 UROLOGY & NEPHROLOGY
H. Nourmohammadi, Tayebe Jamshidbeigi, Zahra Abdan, Diana Sarokhani, M. Fakhri, Shakiba Alaienezhad
{"title":"二甲双胍给药对肾癌患者癌症特异性生存、总生存、无进展生存和疾病进展的影响系统回顾和荟萃分析","authors":"H. Nourmohammadi, Tayebe Jamshidbeigi, Zahra Abdan, Diana Sarokhani, M. Fakhri, Shakiba Alaienezhad","doi":"10.34172/jrip.2023.32158","DOIUrl":null,"url":null,"abstract":"Introduction: The increase in the incidence of renal cell carcinoma (RCC) has been reported worldwide. The anti-cancer impacts of metformin on the various types of cancer have been observed in clinical studies. Therefore, this study aims to survey the effect of metformin use on RCC patients using systematic review and meta-analysis methods. Materials and Methods: In this research, Cochrane, Web of Science, PubMed, Scopus databases, and Google Scholar web browser were searched using standard keywords. Data were analyzed with STATA 14 software. The significance level of tests P<0.05 was considered. Results: The improvement in the progression-free survival (PFS) (HR: 0.72 (95% CI: 0.54, 0.94), P=0.169, I2=37.8%) and cancer-specific survival (CSS) (HR: 0.36 (95% CI: 0.18, 0.75), P=0.339, I2=7.5%) was observed in eight studies with 10404 patients affected by RCC. However, no significant statistical effect was observed on the improvement in the disease progression (OR: 1.10 (95% CI: 0.85, 1.42), P=0.326, I2=0%) and cancer overall survival (OS) (HR: 0.72 (95% CI: 0.51, 1.01), P=0.153, I2=43.1%). Conclusion: This study showed metformin administration improved CSS and PFS in RCC patients. More studies are warranted on the effect of metformin on the improvement in disease progression and OS of cancer. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID= CRD42022369108; https://www.crd.york. ac.uk/prospero/display_record.php?ID=CRD42022369108).","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effect of metformin administration on cancer-specific survival, overall survival, progression-free survival, and disease progression in renal cell carcinoma patients; a systematic review and meta-analysis\",\"authors\":\"H. Nourmohammadi, Tayebe Jamshidbeigi, Zahra Abdan, Diana Sarokhani, M. Fakhri, Shakiba Alaienezhad\",\"doi\":\"10.34172/jrip.2023.32158\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: The increase in the incidence of renal cell carcinoma (RCC) has been reported worldwide. The anti-cancer impacts of metformin on the various types of cancer have been observed in clinical studies. Therefore, this study aims to survey the effect of metformin use on RCC patients using systematic review and meta-analysis methods. Materials and Methods: In this research, Cochrane, Web of Science, PubMed, Scopus databases, and Google Scholar web browser were searched using standard keywords. Data were analyzed with STATA 14 software. The significance level of tests P<0.05 was considered. Results: The improvement in the progression-free survival (PFS) (HR: 0.72 (95% CI: 0.54, 0.94), P=0.169, I2=37.8%) and cancer-specific survival (CSS) (HR: 0.36 (95% CI: 0.18, 0.75), P=0.339, I2=7.5%) was observed in eight studies with 10404 patients affected by RCC. However, no significant statistical effect was observed on the improvement in the disease progression (OR: 1.10 (95% CI: 0.85, 1.42), P=0.326, I2=0%) and cancer overall survival (OS) (HR: 0.72 (95% CI: 0.51, 1.01), P=0.153, I2=43.1%). Conclusion: This study showed metformin administration improved CSS and PFS in RCC patients. More studies are warranted on the effect of metformin on the improvement in disease progression and OS of cancer. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID= CRD42022369108; https://www.crd.york. ac.uk/prospero/display_record.php?ID=CRD42022369108).\",\"PeriodicalId\":16950,\"journal\":{\"name\":\"Journal of Renal Injury Prevention\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-02-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Renal Injury Prevention\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.34172/jrip.2023.32158\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Renal Injury Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jrip.2023.32158","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

导读:肾细胞癌(RCC)的发病率在世界范围内有所增加。临床上已观察到二甲双胍对各类癌症的抗癌作用。因此,本研究旨在通过系统评价和荟萃分析的方法来调查二甲双胍对RCC患者的影响。材料与方法:本研究使用标准关键词检索Cochrane、Web of Science、PubMed、Scopus数据库和谷歌Scholar网络浏览器。采用STATA 14软件对数据进行分析。考虑检验结果P<0.05的显著性水平。结果:在8项研究中,10404例RCC患者的无进展生存期(PFS) (HR: 0.72 (95% CI: 0.54, 0.94), P=0.169, I2=37.8%)和癌症特异性生存期(CSS) (HR: 0.36 (95% CI: 0.18, 0.75), P=0.339, I2=7.5%)均有改善。然而,在改善疾病进展(OR: 1.10 (95% CI: 0.85, 1.42), P=0.326, I2=0%)和癌症总生存(OS) (HR: 0.72 (95% CI: 0.51, 1.01), P=0.153, I2=43.1%)方面,未观察到显著的统计学影响。结论:本研究显示二甲双胍可改善RCC患者的CSS和PFS。二甲双胍对改善癌症进展和生存期的影响有待进一步研究。注册:本研究已根据PRISMA清单编制,其方案已在PROSPERO网站注册(ID= CRD42022369108;https://www.crd.york。ac.uk /普洛斯彼罗/ display_record.php ? ID = CRD42022369108)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The effect of metformin administration on cancer-specific survival, overall survival, progression-free survival, and disease progression in renal cell carcinoma patients; a systematic review and meta-analysis
Introduction: The increase in the incidence of renal cell carcinoma (RCC) has been reported worldwide. The anti-cancer impacts of metformin on the various types of cancer have been observed in clinical studies. Therefore, this study aims to survey the effect of metformin use on RCC patients using systematic review and meta-analysis methods. Materials and Methods: In this research, Cochrane, Web of Science, PubMed, Scopus databases, and Google Scholar web browser were searched using standard keywords. Data were analyzed with STATA 14 software. The significance level of tests P<0.05 was considered. Results: The improvement in the progression-free survival (PFS) (HR: 0.72 (95% CI: 0.54, 0.94), P=0.169, I2=37.8%) and cancer-specific survival (CSS) (HR: 0.36 (95% CI: 0.18, 0.75), P=0.339, I2=7.5%) was observed in eight studies with 10404 patients affected by RCC. However, no significant statistical effect was observed on the improvement in the disease progression (OR: 1.10 (95% CI: 0.85, 1.42), P=0.326, I2=0%) and cancer overall survival (OS) (HR: 0.72 (95% CI: 0.51, 1.01), P=0.153, I2=43.1%). Conclusion: This study showed metformin administration improved CSS and PFS in RCC patients. More studies are warranted on the effect of metformin on the improvement in disease progression and OS of cancer. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID= CRD42022369108; https://www.crd.york. ac.uk/prospero/display_record.php?ID=CRD42022369108).
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Renal Injury Prevention
Journal of Renal Injury Prevention UROLOGY & NEPHROLOGY-
CiteScore
1.60
自引率
0.00%
发文量
36
期刊介绍: The Journal of Renal Injury Prevention (JRIP) is a quarterly peer-reviewed international journal devoted to the promotion of early diagnosis and prevention of renal diseases. It publishes in March, June, September and December of each year. It has pursued this aim through publishing editorials, original research articles, reviews, mini-reviews, commentaries, letters to the editor, hypothesis, case reports, epidemiology and prevention, news and views and renal biopsy teaching point. In this journal, particular emphasis is given to research, both experimental and clinical, aimed at protection/prevention of renal failure and modalities in the treatment of diabetic nephropathy. A further aim of this journal is to emphasize and strengthen the link between renal pathologists/nephropathologists and nephrologists. In addition, JRIP welcomes basic biomedical as well as pharmaceutical scientific research applied to clinical nephrology. Futuristic conceptual hypothesis that integrate various fields of acute kidney injury and renal tubular cell protection are encouraged to be submitted.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信